메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Few efforts have been made to integrate a next generation sequencing (NGS) panel into standard clinical treatment ofovarian cancer. The aim of this study was to investigate the clinical utility of NGS and to identify clinically impactful informationbeyond targetable alterations. Materials and Methods: We conducted a retrospective review of 84 patients with ovarian cancer who underwent NGS betweenMarch 1, 2017, and July 31, 2018, at the Yonsei Cancer Hospital. We extracted DNA from formalin-fixed, paraffin-embedded tissuesamples of ovarian cancer. The TruSight Tumor 170 gene panel was used to prepare libraries, and the MiSeq instrument wasused for NGS. Results: Of the 84 patients, 55 (65.1%) had high-grade serous carcinomas. Seventy-three (86.7%) patients underwent NGS at the timeof diagnosis, and 11 (13.3%) underwent NGS upon relapse. The most common genetic alterations were in TP53 (64%), PIK3CA (15%),and BRCA1/2 (13%), arising as single nucleotide variants and indels. MYC amplification (27%) was the most common copy numbervariation and fusion. Fifty-seven (67.9%) patients had more than one actionable alteration other than TP53. Seven (8.3%) casesreceived matched-target therapy based on the following sequencing results: BRCA1 or 2 mutation, poly ADP ribose polymeraseinhibitor (n=5); PIK3CA mutation, AKT inhibitor (n=1); and MLH1 mutation, PD-1 inhibitor (n=1). Fifty-three (63.0%) patients hada possibility of treatment change, and 8 (9.5%) patients received genetic counseling. Conclusion: Implementation of NGS may help in identifying patients who might benefit from targeted treatment therapies andgenetic counseling.

목차

등록된 정보가 없습니다.

참고문헌 (16)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0